

Synthesis, Characterization and Microbial Activity of 5-[1-(1,3-Benzothiazol-2-Ylsulfanyl)Alkyl]-1,3,4-Thiadiazole-2-(3h)-Thione

Debojyoti Chakraborty, Sita Ram Sharma and L.K.Mish

National Institute of Technology, India, Bihar, Patna-5

Abstract- A number of benzothiazole-2-ylsulfanyl derivatives 2-(1,3-Benzothiazol-2-ylsulfanyl)alkanoylhydrazide (IA – IG) and 5-[1-(1,3-Benzothiazol-2-ylsulfanyl)alkyl]-1,3,4-thiadiazole-2-(3H) thione (IIA-IIG) have been synthesised from (1,3-Benzothiazol-2-ylsulfanyl)acetic acid. These compounds were synthesised and characterized from their F.T.I.R, and H-NMR spectral studies. The compound (IIA to IIG) were screened for antibacterial activity and antifungal properties. The compound 2A-2G showed appreciable antifungal and antibacterial activity.

Index Terms- Benzothiazole derivatives, synthesis, Microbial activity.


I. INTRODUCTION

The benzimidazole and benzothiazole derivatives are most promising molecules for pharmacological point of view^{1,2}. A large number of benzothiazole and benzimidazole derivatives are used as potential drugs in treatment of various diseases³⁻⁵. A considerable number of benzothiazole and benzimidazole derivatives are used as antidiabetic⁶, antihistaminic⁷, analgesic⁸, antiviral⁹, Chemotherapeutic¹⁰, antifungal¹¹, antiparasitic¹², antiulcer¹³, antiHIV¹⁴, anticancer¹⁵ and antibiotic¹⁶ substances.

II. RESULT AND DISCUSSION


2-Mercaptobenzothiazole(BtH) reacts with potassium salt of 2-Chloroacetic acid or related α -chloroalkanoic acid in presence of K_2CO_3 to yield 2-(1,3-benzothiazol-2-ylsulfanyl)alkanoic acid (as shown in Scheme-I). The alkanic acid derivatives are converted to its ethyl ester with dry ethanol in presence of catalytic amount of conc. H_2SO_4 . The ester on refluxing with 98% hydrazine gave 2-(1,3-benzothiazol-2-ylsulfanyl)alkanoylhydrazide(IA to IG).

Scheme-I



The group R taken for IA to IG are
 IA = H, IB = -CH₃, IC = -CH₂-CH₃, ID = -CH₂-CH₂-CH₃, IE = -CH₂-CH(CH₃)₂, IF = -CH₂(CH₂)₂-CH₃ and IG = -CH₂-C₆H₅

The alkanoylhydrazide (IA to IG) were prepared crystallised, analysed and these were used to synthesised the thiadiazole derivative (2A to 2G). The interaction of alkanoyl hydrazide (IA to IG) with CS₂ in pyridine on refluxing gave thiadiazole derivatives 2A-2G (BTATDT) according to **Scheme-2**



The products BTATH are major product while oxadiazole (BTAOT) were obtained in small fraction in impure form are not being reported.

EXPERIMENTAL

The organic chemical used were obtained from BDH, E Merck, Fluka (Germany), Sigma Aldrich, Loba chem. And Sd fine chemicals. The solvents used were extrapure chemical. The meeting points of compounds were determined by open capillary tube and are uncorrected. The ¹HNMR and ¹³CNMR spectral of compounds were recorded at C.D.R.I Lucknow and FTIR spectra spectra at IIT Patna. The microbial tests were performed at Biotechnology, Department of Science College, Patna.

Elemental analysis of compounds were obtained from BIT Mesra, Ranchi (Vario EL CHNS analyser) Mass and Electronic absorption spectra were recorded at IIT Patna.

Preparation of compounds:

The compound 5-[1-(1,3-benzothiazol-2-ylsulfanyl)alkyl]-1,3,4-thiadiazole-2-(3H)-thione (2A-2G) were prepared from 2-mercaptobenzothiazole, α -Chloroalkanoic acid, hydrazine and carbon disulphide in three steps as out lined in **Scheme-I**.

Step I, II

Preparation of 2-[1,3-benzothiazol-2-ylsulfanyl]alkanoylhydrazide (IA-IG) from 2-Mercapto1,3-benzothiazole.

Step III

Preparation of 5-[1-(1,3-Benzothiazol-2-ylsulfanyl)alkyl]-1,3,4-thiadiazole-2-(3H)-thione from IA to IG.

Procedure of preparation of IA to IG.

These compounds were synthesised by common procedure from 1,3-Benzothiazol-2-ylthiol.

Step-I

About 0.1 mole 2-mercaptobenzothiazol was taken in 50 ml aqueous ethanol and treated with 6 gram K₂CO₃ (0.05 moles). The resulting solution was heated on a steam bath with 0.1 mole of potassium salt of chloroacetic acid dissolved in 20 ml aqueous ethanol for two to three hours and left over night. The cold solution was neutralised with dilute hydrochloric acid and free 2-(1,3-benzothiazol-2-ylsulfanyl)acetic acid separated was filtered and dried in desiccator. (Yeild 96-97%).

Step-II

The prepared acid (0.05 mol) was dissolved in 30 ml dry ethanol and treated with 0.5-1 ml conc H₂SO₄ and refluxed on water bath for 3 to 4 hours and excess of ethanol was removed by distillation. The ester formed was treated with 20 ml hydrazine hydrate (98%) heated on steam bath at 60- 70°C for 4-5 hours and left overnight. The resulting product was suspended in 30-40 ml water to remove soluble hydrazine sulphate. The water insoluble 2-(1,3-benzothiazol-2-ylsulfanyl)alkanoylhydrazide was filtered and recrystallised with hot ethanol. The M.P and analytical results of compound IA to IG are given in **Table-I**
Synthesis of 5-[1-(1,3-benzothiazol-2-ylsulfanyl)alkyl]-1,3,4-thiadiazole (2A to 2B)

These compounds were prepared by same common procedure.
Procedure:

About 0.02 mole of 2-(1,3-benzothiazol-2-ylsulfanyl)alkanoylhydrazide was taken in 20 ml distilled pyridine and treated with 2.5 ml carbon disulphide and resulting mixture was refluxed on steam bath for 3-4 hours till evolution of H₂S ceased. The excess of pyridine was distilled at reduced pressure when yellow viscus mass was left. The product was dissolved in hot ethanol and insoluble portion probably impure oxadiazole derivative was rejected. The solution on cooling gave crystalline precipitate of pyridinium salt of 5-[1-(1,3-benzothiazol-2-ylsulfanyl)alkyl]-1,3,4-Thiadiazole were obtained. The product was suspended in hot water and neutralised with dilute HCl to liberate free 1,3,4-Thiadiazole derivatives 2A -2G. The yield was 70-75%. The product was recrystallised with hot ethanol tetrahydrofuran mixture.

The products were analysed and results of C,H,N,S analysis reported in **Table-I**

Table-1
Elemental analysis of compound 1A-1G and 2A – 2G


| Comps-M.P ⁰ C (Formula) | % Elemental analysis- Found (Calculated) | | | |
|--|--|-------------|---------------|---------------|
| | C | H | N | S |
| 1A- 269 (C ₉ H ₉ N ₃ S ₂ O) | 45.36 (45.18) | 3.61 (3.76) | 17.36 (17.57) | 26.41 (26.77) |
| 1B- 262 (C ₁₀ H ₁₁ N ₃ S ₂ O) | 47.31 (47.43) | 4.31 (4.35) | 16.40 (16.60) | 25.11 (25.29) |
| 1C-259 (C ₁₁ H ₁₁ N ₃ S ₂ O) | 49.13 (49.43) | 4.53 (4.86) | 15.61 (15.73) | 23.61 (23.97) |
| 1D- 263 (C ₁₂ H ₁₅ N ₃ S ₂ O) | 51.10 (51.24) | 5.11 (5.33) | 14.71 (14.94) | 22.11 (22.27) |
| 1E-267 (C ₁₂ H ₁₅ N ₃ S ₂ O) | 51.34 (51.24) | 5.31 (5.33) | 14.78 (14.94) | 22.41(22.27) |
| 1F-269 (C ₁₃ H ₁₇ N ₃ S ₂ O) | 52.28(52.88) | 5.61(5.76) | 14.10(14.23) | 21.41(21.69) |
| 1G-284 (C ₁₆ H ₁₅ N ₃ S ₂ O) | 58.11 (58.36) | 4.41(4.55) | 12.71(12.76) | 19.16(19.45) |
| 2A-281 (C ₁₀ H ₇ N ₃ S ₄) | 40.61 (40.40) | 2.46 (2.35) | 14.36(14.4) | 43.01(43.09) |
| 2B-278 (C ₁₁ H ₉ N ₃ S ₄) | 42.32 (42.44) | 2.96(2.89) | 13.69 (13.50) | 41.23 (41.15) |
| 2C-273 (C ₁₂ H ₁₁ N ₃ S ₄) | 44.16 (44.30) | 3.28 (3.38) | 12.93 (12.92) | 39.18 (39.38) |
| 2D-275 (C ₁₃ H ₁₃ N ₃ S ₄)? | 45.84 (46.01) | 3.93 (3.83) | 12.56 (12.38) | 37.69(37.75) |
| 2E-269 (C ₁₃ H ₁₃ N ₃ S ₄)? | 45.78 (46.01) | 4.01(3.83) | 12.41(12.38) | 37.57 (37.75) |
| 2F-280 (C ₁₄ H ₁₅ N ₃ S ₄) | 47.41(47.59) | 4.12(4.24) | 11.73(11.89) | 36.01(36.26) |
| 2G-294 (C ₁₇ H ₁₃ N ₃ S ₄) | 52.41(52.71) | 3.51(3.36) | 10.78(10.85) | 32.90(33.07) |

Table-4

¹HNMR results of IA – IG and 2A -2G
¹HNMR Spectra for some hydrazide A-G and finally isolated mixed benzothiazole-2-ylsulfanylmethyl substituted 1,3,4-thiadiazole-2-(3H)-thiones were recorded in DMSO or CDCl₃.

The ¹HNMR signals of compounds recorded are tabulated in **Table-4**. ¹³CNMR spectra of few samples were recorded at CDRI Lucknow to support the structure of thiadiazole derivatives.

The ^1H NMR spectrum of 2-(1,3-benzothiazol-2-ylsulfanyl)ethanoic acid hydrazide (I-A) shows (-S-CH₂-CO) proton signal as singlet at $\delta = 4.215$ ppm and phenyl ring



2-(1,3-benzothiazol-2-ylsulfanyl)acetohydrazide (IA)

proton signals between $\delta = 7.346$ -7.874 ppm as multiplet. The NH and NH₂ proton signals were observed at $\delta = 8.001$ and 8.027 ppm. The ^1H NMR proton signal are consistent with structure of hydrazide I-A. The ^1H NMR spectrum of sulfanylpropanoylhydrazide (I-B) shows -CH₃ proton signals as double at 2.165 and 2.195 ppm and (S-CH-CO) proton signals as quarterate at 4.125-4.179 ppm with J value 18 Hz. The phenyl ring (CH) signals were obtained as multiplete $\delta = 7.384$ -7.804 ppm and NH as well as NH₂ proton band at 8.121-8.189 ppm. ^1H NMR signal of phenylethanoic acid derivative hydrazide I-G shows (S-CH-CO) proton signal at 4.282 ppm as singlet and phenyl as well as benzothiazole phenyl ring (CH) proton band as multiplete between $\delta = 7.046$ and 7.874 ppm.

I-A, 2-(1,3-Benzothiazol-2-ylsulfanyl)ethanolyhydrazide (C₉H₉N₃S₂O) (S-CH₂-CO) proton signal, singlet $\delta = 4.215$ ppm, phenyl ring (C—H) proton band multiplet $\delta = 7.346$ -7.874 ppm. NH₂ and NH proton bands $\delta = 8.001$ and 8.027 ppm.

IB, 2-(1,3-benzothiazol-2-ylsulfanyl)propanoylhydrazide (C₁₀H₁₁N₃S₂O), (S-CH(CH₃)-CO) group CH₃ proton signals as double $\delta = 1.795$ & 1.803. J value 8 Hz and (S-CH-CO) proton signals as quartrate $\delta = 4.173$ - 7.195 ppm. The phenyl ring proton signals as multiplet $\delta = 7.287$ -7.875 ppm. The -NH₂ and NH proton signals at $\delta = 8.125$ and $\delta = 8.186$ ppm.

1C, 2-(1,3-benzothiazol-2-ylsulfanyl)butanoylhydrazide (C₁₁H₁₃N₃S₂O), (S-CH(Et)-CO) group -CH₂-CH₃ proton

signals as multiplet $\delta = 1.735$ -1.815 ppm, and (S-CH-CO) proton as triplet $\delta = 4.215$ -4.224 ppm. The phenyl ring (CH) band $\delta = 7.268$ -7.728 ppm as multiplet for 4 proton. The -NH₂ and NH proton band at $\delta = 8.176$ and 8.248 ppm as broad band.

IR Spectra

The spectrum of IA shows NH₂ and NH stretches at 3310, 3245 and 3175 cm⁻¹. The ν CO band of IA was observed as strong band at 1672 cm⁻¹. A medium band at 1625 cm⁻¹ is attributed to -NH₂ deformation vibration and strong band at 1595 cm⁻¹ as ring (C=N) stretch. The δ NH of hydrazide was assigned to a IR band at 1508 cm⁻¹. The prominent i.r bands of 2-(1,3-benzothiazol-2-ylsulfanyl)alkanoyl hydrazide are given in **Table C**. The occurrence of ν (CO) band between 1670-1685 and NH₂ and NH stretches between 3342-3140 cm⁻¹ as well as benzothiazole ring ν (C=N) stretch between 1590-1602 cm⁻¹ are consistent with assigned structure of 1-A to 1G. The i.r spectra of 5-[1-(1,3-benzothiazol-2-ylsulfanyl)methyl]-1,3,4-thiadiazole-2-(3H)-thione in KBr disc show the absence of ν (CO) stretche near 1670-1685 cm⁻¹ supporting the cyclization of alkanoyl hydrazide (-CO-) group. The ring (N-H) stretch was observed as medium band at 3310-3240 cm⁻¹ and alkyl CH stretching frequency was observed medium band at 2860-2960 cm⁻¹. The ring ν (C=N) was observed at 1605-1593 cm⁻¹ and thione ν (C=S) vibration between 1306-1330 cm⁻¹. The ring (C-S-C) stretch was assigned to a medium band at 698-712 cm⁻¹. The prominent i.r bands of compound 2A to 2G are recorded in **Table-D**. The i.r spectral bands of ν (C=N), ν (C=S), ν (C—S—C) and ring (N-H) vibration are consistent with thione structure of compound 2A-2G.

Table-2
Diagnostic IR bands of compound 1A to 1G in cm⁻¹

| Compo und | NH ₂ & NH stretches | CH ₂ , CH- stretch | ν (CO) | δ (NH ₂) | ν (CN) | δ (NH) | ν (CSC) |
|-----------|--------------------------------|-------------------------------|------------|-----------------------------|------------|---------------|-------------|
| 1A | 3310, 3245, 3145 | 3045, 2940 | 1672 | 1625 | 1595 | 1508 | 726 |
| 1B | 3315, 3240 | 3052, 2945, 2840 | 1670 | 1622 | 1596 | 1512 | 715 |
| 1C | 3318, 3215, 3142 | 3096, 2942, 2865 | 1678 | 1626 | 1590 | 1501 | 721 |
| 1D | 3341, 3248, 3147 | 3055, 2945, 2862 | 1676 | 1620 | 1592 | 1506 | 728 |
| 1E | 3301, 3218, 3116 | 3042, 2940, 2861 | 1682 | 1626 | 1594 | 1512 | 725 |
| 1F | 3342, 3218, 3140 | 3060, 2928, 2865 | 1674 | 1623 | 1597 | 1501 | 706 |
| 1G | 3301, 3205, 3162 | 3045, 2922, 2842 | 1685 | 1618 | 1602 | 1506 | 723 |

Table-3
Prominent IR bands of compound 2A – 2G

| Compound | ν (NH) + ν (C-H) | ν (CH ₂) | ν (C=N) | ν (C=S) | ν (NH) | ν (C-S-C) |
|----------|--------------------------|--------------------------|-------------|-------------|------------|---------------|
| 2A | 3284, 2928 | 2840 | 1604 | 1322 | 1482 | 705 |
| 2B | 3302, 2920 | 2862 | 1601 | 1318 | 1484 | 712 |

| | | | | | | |
|----|------------|------|------|------|------|-----|
| 2C | 3240, 2942 | 2862 | 1595 | 1312 | 1495 | 707 |
| 2D | 3215, 2941 | 2855 | 1593 | 1321 | 1491 | 698 |
| 2E | 3302, 2925 | 2861 | 1601 | 1328 | 1501 | 710 |
| 2F | 3295, 2960 | 2847 | 1596 | 1306 | 1505 | 705 |
| 2G | 2309, 3010 | 2910 | 1604 | 1330 | 1501 | 707 |

REFERENCES

- [1] Habib N. S & El Hawash S A. *II Farmaco*, 1989,44. 1225-1232
- [2] Anton V D, Wai-Keung C, Anna V D & Lai-Wah C, *J Fluorine chem.*, 2005,126. 759
- [3] Kuhler T C, Swanson M, Christenson B, Klintonberg A, Lamm B, Fagerhag J, Olwegard-Halvarson M, Shecherbuehin V, Elbrring T & Sjstrom J, *J Med Chem*, 2002,45, 4282
- [4] Omar M T, *Egypt J Pharma Sci*, 1997, 38, 281
- [5] Hopkins K T, Wilson W D, Bender B C, Mc-Curdy D R & Boykin D W, *J Med Chem*, 1998,41, 3872
- [6] Hakan G, Scrif O, Yildez S & Boykin D W, *Eur J Med Chem*, 2005,40, 1069
- [7] Yildiz-Oren I, Yalcin I, Aki-Sener E & Ukarturk N, *Eur J Med Chem*, 2004, 39, 291
- [8] Pawar N S, Dalal D S, Shimpi S R & Mahulikar P P, *Eur J Phar Sci*, 2004, 21, 115.
- [9] Ismail M A, Brun R, Tanious F A, Wenzler T, Wilson W D & Boykin D W, *Bioorg Med Chem*, 2004,12, 5405
- [10] Ismaiel A M, Yousif M Y, Metwally M A & El-Kerdawy M M, *Indian J Chem*, 1984,23B, 489
- [11] Goker, H.; Kus, C.; Abbasoglu, U. *Arch. Pharm. (Weinheim)* 1995, 328, 425-430.
- [12] Garuti, L.; Roberti, M.; Gentilomi, G. *II Farmaco* 2000, 55, 35-39.
- [13] Shinichi, K.; Kosaku, F.; Takashi, F. *Chem. Abstr. PCT. Int. Appl. WO.0105402. 2001, 134, 131531g.*
- [14] Janssens, F.; Torremans, J.; Janssen, M.; Stokbroekx, R. A. *J. Med. Chem.*1985, 28, 1925-1933.
- [15] Uzunoglu, S.; Tosun, A.; Ozden, T.; Yesilada, E. *Hacettepe. Univ.Eczacilik. Fak. Derg. (Persian)* 1997, 17, 17-24.
- [16] Fanqi, Q.; Xinrong, D.; Xinxiang, L.; Xin, L.; Xiaoling, H. *J. Nat. Sci.* 1998,3, 201-204.
- [17] Sermin, U.; Bilge, C.; Tosun, A.; Fethi, S. M.; Berrin, O. *Hacettepe. Univ.Eczacilik. Jak. Derg. (Persian)* 1997, 17, 47-53.
- [18] Samuel, H. N.; Rida, S. M.; Badawey, E. A. M.; Fahmy, H. T. Y.; Ghozlan, H. A. *Pharmazie* 1997, 52, 346-350.
- [19] Laura, G.; Marinella, R.; Annalisa, P.; Emanuela, L. *Bioorg. Med Chem.Lett.* 2001, 11, 3147-3149.
- [20] Anshul Chawla, Ramandeep Kaur and Anju Goyl. *J.Chem.Pharma Res*, 2011,3(6), 925-944
- [21] L.C.R.Carvalho, M.M.B.Marques and E.Fernandes, *Chem.Eur.J.* 2011,17,12544-12555
- [22] (a) Eisa H.M, Barghash A.M, Badr S.M, Farahat A.A; *Indian J. Chem.*2012, 49B, 1515-1525 (b) Ravishankara D.K and Chandrashekara P.G;*Eur J.Chem.*2012,3(3)359-362
- [23] Nakamoto K; *The Infrared and Raman Spectra of Inorganic and Coordination Compound.* Wiley Interscience, New York, 1978
- [24] Belamy L.J; *The Infrared Spectra of Complex Molecule.* 2nd Edition, Chapman and Hall, London, 1980
- [25] Whitehead M.D; *Phytopath.*, 1952,550
- [26] Dubey R.K, Mariya A; *J.Indian Chem.Soc.*, 2012 89,51,
- [27] (a) Collins C.H, *Microbiological methods*, (Butterworths, London), 1964, p92 (b) Lorian V, *Antibiotics in Laboratory Medicine* (Williams and Wikins, Baltimore, London),1980,p1014

AUTHORS

First Author – Debojyoti Chakraborty, National Institute of Technology, India, Bihar, Patna-5, Email Id:- pomchem@gmail.com

Second Author – Sita Ram Sharma, National Institute of Technology, India, Bihar, Patna-5

Third Author – L.K.Mishra, National Institute of Technology, India, Bihar, Patna-5